30 January 2025
Physiomics plc
("Physiomics" or the "Company")
Trading Update
Physiomics plc (AIM: PYC), a leading
mathematical modelling, data science and biostatistics company
supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce that it is trading in
line with market expectations for the full year ending 30 June
2025.
The Board expects that total income for the
current financial year, driven by contracts already signed, will be
in line with market expectations. The Company is actively
discussing a number of further contracts although there is no
guarantee they will be signed within the current financial
year.
The Board also expects the Company's loss after
tax for the same period will be slightly lower than current
expectations. The Company has worked hard to maintain or increase
its day rates with key customers and continues to improve
operational efficiencies, both of which have contributed to the
improved loss position.
The Company also notes that it expects to
report its Interim Results for the six months ended 31 December
2024 in early March 2025.
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Limited (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines expertise
across Modelling & Simulation, Biostatistics, Data Science and
Bioinformatics, together with deep biology expertise, to help
biotech and pharma companies streamline their drug development
journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and
clinical studies. Through use of cutting-edge computational tools,
bespoke models and our proprietary Virtual Tumour technology, the
Physiomics team has informed the development of over 100 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
This announcement contains inside information for the purposes
of article 7 of the Market Abuse Regulation (EU) 596/2014 as
amended by regulation 11 of the Market Abuse (Amendment) (EU Exit)
Regulations 2019/310. With the publication of this announcement,
this information is now considered to be in the public
domain.
